Time to put boots on the ground: Making universal access to MDR-TB treatment a reality

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 10, 2010, Pages 1222-1225

  Keshavjee, S ^a,b,c   Farmer, P E ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c PARTNERS IN HEALTH   (United States)

Author keywords

Multidrug resistant tuberculosis; Poverty; Pragmatic solidarity; Technical accompaniment; Treatment scale up

Indexed keywords

ISONIAZID; RIFAMPICIN;

DRUG SENSITIVITY; EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HUMAN; INFECTION RISK; MULTIDRUG RESISTANT TUBERCULOSIS; POVERTY; PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; COOPERATIVE BEHAVIOR; DEVELOPING COUNTRIES; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; INTERNATIONAL COOPERATION; NATIONAL HEALTH PROGRAMS; POVERTY; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 77957049363     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (22)

1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO, 2010.
2. World Health Organization. World health report 2010. Health systems: improving performance. Geneva, Switzerland: WHO, 2000.
3. United Nations Development Programme. Human development report 2009. Overcoming barriers: human mobility and development. New York, NY, USA: Palgrave Macmillan, 2009.
4. Farmer P E. Infections and inequalities: the modern plagues. Berkeley, CA, USA: University of California Press, 2001.
5. Farmer P E, Nizeye B, Stulac S, Keshavjee S. Structural violence and clinical medicine. PLoS Med 2006; 3(10): 1686-1991.
6. Keshavjee S, Gelmanova I, Pasechnikov A, et al. Treating multi-drug resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease. Ann N Y Acad Sci 2008; 1136: 1-11.
7. Shin S, Furin J, Bayona J, Mate K, Kim J Y, Farmer P. Community based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med 2004; 59: 1529-1539.
8. Partners In Health, Harvard Medical School, Brigham and Women's Hospital. The PIH guide to the medical management of multidrug-resistant tuberculosis. International edition. Boston, MA, USA: Partners In Health, 2003.
9. Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 33: 229-233.
10. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128. (Pubitemid 36056718)
11. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006; 10: 402-408.
12. Keshavjee S, Seung K, Satti H, et al. Building capacity for multidrug-resistant tuberculosis treatment: health systems strengthening in Lesotho. Innovations 2008; 2: 87-106.
13. Seung K J, Omatayo D, Keshavjee S, et al. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS ONE 2009; 4(9): e7186(1-7).
14. World Health Organization/International Union Against Tuberculosis and Lung Disease. Global project on anti-tuberculosis drug resistance in the world. Report no. 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
15. World Health Organization. Stop TB Strategy: building on and enhancing DOTS to meet the TB-related Millennium Development Goals. WHO/HTM/TB/2006.368. Geneva, Switzerland: WHO, 2006.
16. World Health Organization. World Health Assembly Resolution 62.15: Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. WHA62.15. Geneva, Switzerland: WHO, 2009.
17. Chan M. MDR-TB: overcoming resistance is essential. Opening remarks, Pacific Health Summit, Seattle, WA, USA, June 18, 2009. http://www.who.int/dg/ speeches/2009/mdr-tb-resistance-20090618/en/index.html Accessed July 2010.
18. Paramasivan C N, Lee E, Kao K, et al. Experience establishing tuberculosis laboratory capacity in a developing country setting. Int J Tuberc Lung Dis 2010; 14: 59-64.
19. Gelmanova I Y, Keshavjee S, Golubchikova V T, et al. Barriers to successful tuberculosis treatment in Tomsk, Russia; non-adherence, default, and the acquisition of multi-drug resistance. Bull World Health Organ 2007; 85: 703-711.
20. Jakubowiak W M, Bogorodskaya E M, Borisov S E, Danilova I D, Kourbatova E V. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis 2007; 11: 46-53. (Pubitemid 46101845)
21. Keshavjee S, Seung K. Stemming the tide of multidrug-resistant tuberculosis: major barriers to addressing the growing epidemic. In: Institute of Medicine. Addressing the threat of drug resistant tuberculosis: a realistic assessment of the challenge. Workshop summary. Washington DC, USA: National Academies Press, 2009.
22. World Health Organization. Pandemic (H1N1) 2009 - update 110. July 23, 2010. http://www.who.int/csr/don/2010-07-23a/en/index.html Accessed July 2010.